2019 - All Press Releases

Springer Nature and DrugPatentWatch partner to provide patent information for drug database

Newly available patent information supports researchers in their strategic decision-making in drug discovery

Heidelberg | London | New York, 11 April 2019

A new module focusing on patents has been added to the drug pipeline tool AdisInsight. The module allows users to find out which drugs have been patented and when regulatory protection may expire. 

“Drug patent information can help key stakeholders in the drug discovery process understand the impact of patent expiry on the competitive landscape, or their market share. They may also be able to evaluate licensing opportunities and explore what opportunities exist for drugs without patent protection, as well as develop end-of-life strategies for their products,” explained Dr. Yali Friedman, Chief Executive of DrugPatentWatch.

Jeff Southwood, Product Development Director for AdisInsight, said: “One of the major struggles our users face is that they have to rely very heavily on patent attorneys or IP specialists to assess patent protection because of the expertise required to find this information in patent-specific databases and to understand and interpret these complex documents. Our goal in developing AdisInsight Patents is to advance the drug discovery process by making drug-centric patent information accessible to any user by including familiar search terms and at-a-glance summaries.”

DrugPatentWatch, a provider of global business intelligence on biologic and small molecule drug patents, will deliver the patent content to AdisInsight. The new AdisInsight patents module is available for existing AdisInsight customers to purchase as an add-on to their subscription or to new subscribers to the platform.   

Further Information

AdisInsight can be accessed here. A demonstration of the new patents module can be requested via: asktheexpert.adisinsight@springer.com 

About DrugPatentWatch

DrugPatentWatch is a provider of global business intelligence on biologic and small-molecule drugs, dedicated to helping clients make better decisions. Critical information on global drug patents is incorporated with litigation intelligence, drug prices, and historic sales figures to help users discover commercial opportunities and forecast future revenue events. Visit: drugpatentwatch.com 

About Springer Nature

Springer Nature is a leading research, educational and professional publisher, providing quality content to our communities through a range of innovative platforms, products and services. Every day, around the globe, our imprints, books, journals and resources reach millions of people – helping researchers, students, teachers and professionals to discover, learn and achieve more. Through our family of brands, we aim to serve and support the research, education and professional communities by putting them at the heart of all we do, delivering the highest possible standards in content and technology, and helping shape the future of publishing for their benefit and for society overall. Visit: springernature.com/group and follow @SpringerNature.


Elizabeth Hawkins | Springer Nature | Communications
tel +49 6221 487 8130 | elizabeth.hawkins@springernature.com